NCT05180890View on ClinicalTrials.gov

A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
Sleep Apnea
Interventions
DRUG

Danavorexton

Danavorexton intravenous infusion.

DRUG

Placebo

Placebo intravenous infusion.

Trial Locations (1)

5042

Adelaide Institute for Sleep Health (AISH), Flinders University, Adelaide

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05180890 - A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter